Table 3. Cox regression analyses for CSS and OS in patients with prostate cancer.
| Parameters | CSS | OS | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| 1CTP-RIA ≥ median vs. < median | 1.69 | 0.65–5.24 | 0.296 | 1.52 | 0.63–4.25 | 0.362 | |
| PSA-DT ≥6 vs. <6 months | 1.38 | 0.53–3.66 | 0.503 | 1.36 | 0.58–3.21 | 0.475 | |
| ≥ Age median vs. < age median in PCcM1b | 1.80 | 0.71–4.55 | 0.214 | 1.41 | 0.62–3.18 | 0.400 | |
| M1b only vs. additional M1a or M1c | 3.04 | 0.93–9.70 | 0.065 | 3.63 | 1.30–10.07 | 0.015 | |
CSS, cancer-specific survival; OS, overall survival; PSA, prostate-specific antigen; DT, doubling time; M1b, bone metastases; M1a, extraregional lymph node metastases; M1c, visceral metastases.